SNF.Back to Emerging
Emerging Detail

LTGO - Latigo Biotherapeutics, Inc.

Candidate

SNF Emerging Watchlist(TM) tracks newly public companies positioned around emerging economic themes. Inclusion reflects SNF research interest and ongoing monitoring; it is not a recommendation to buy, sell, or hold a security.

Emerging Score
80 / 100
Confidence
92%
Band
Strong Emerging Profile
Last Reviewed
Oct 23, 2026
Primary Theme
Biotechnology / Health Innovation
Exchange
Nasdaq
Current Thesis

Structural Theme Relevance

What Changed

Candidate to Candidate review completed.

Why It Matters

Structural Theme Relevance

What The Market Is Pricing In

Market Confirmation currently scores 50/100 within the Emerging Score framework.

What Could Change The Narrative

Phase 3 execution and reproducing efficacy at pivotal scale

SNF Lens
Signal
Structural Theme Relevance
Noise
Some evidence needs refresh context.
Confirmation
Market Confirmation 50/100
Risk
Phase 3 execution and reproducing efficacy at pivotal scale
Six-Family Scorecard
Structural Theme Relevance
82
Business Quality
82
Growth / Traction
88
Competitive Position
80
Financial Durability
88
Market Confirmation
50
Key Risks
Phase 3 execution and reproducing efficacy at pivotal scale
Clinical safety, timeline slippage and long-term financing needs
Evidence Quality
Active Evidence
6
Sources
3
Stale Evidence
1
Freshness
Mixed freshness
Review / Score History
Oct 23, 2026Thesis unchanged - Candidate unchanged
Oct 4, 2026Thesis unchanged - Candidate unchanged
Sep 18, 2026Thesis strengthened - Candidate unchanged
Oct 23, 2026Score 80 / Confidence 92 / Candidate
Oct 4, 2026Score 80 / Confidence 92 / Candidate
Sep 18, 2026Score 80 / Confidence 92 / Candidate
Sep 1, 2026Score 79 / Confidence 88 / Candidate
Sources
investors.latigobio.com
earnings-release - Sep 3, 2026
Open source
Market Data
market-data - Sep 17, 2026
investors.latigobio.com
company-ir - Jul 29, 2026
Open source